Board Change • Jul 15
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Jimmy Chang was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. New Risk • Jun 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • May 15
First quarter 2026 earnings released: NT$0.099 loss per share (vs NT$0.084 profit in 1Q 2025) First quarter 2026 results: NT$0.099 loss per share (down from NT$0.084 profit in 1Q 2025). Revenue: NT$110.4m (down 16% from 1Q 2025). Net loss: NT$11.3m (down 218% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. New Risk • Apr 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.16b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (2.4% net profit margin). Market cap is less than US$100m (NT$3.16b market cap, or US$99.7m). New Risk • Mar 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (2.4% net profit margin). Reported Earnings • Feb 16
Full year 2025 earnings released: EPS: NT$0.10 (vs NT$0.22 in FY 2024) Full year 2025 results: EPS: NT$0.10 (down from NT$0.22 in FY 2024). Revenue: NT$492.4m (down 3.6% from FY 2024). Net income: NT$11.7m (down 55% from FY 2024). Profit margin: 2.4% (down from 5.0% in FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. New Risk • Feb 16
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.4% Last year net profit margin: 5.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (2.4% net profit margin). Annonce • Jan 28
Genovate Biotechnology Co., Ltd., Annual General Meeting, Apr 22, 2026 Genovate Biotechnology Co., Ltd., Annual General Meeting, Apr 22, 2026, at 09:00 Taipei Standard Time. Location: no,1, kung yeh 1st rd., hukou township, hsinchu county Taiwan New Risk • Jan 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Annonce • Jan 08
Genovate Biotechnology Co., Ltd. has filed a Follow-on Equity Offering in the amount of TWD 644 million. Genovate Biotechnology Co., Ltd. has filed a Follow-on Equity Offering in the amount of TWD 644 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 20,700,000
Price\Range: TWD 28
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,300,000
Price\Range: TWD 28
Transaction Features: Reserved Share Offering; Rights Offering Reported Earnings • Nov 13
Third quarter 2025 earnings released: NT$0.01 loss per share (vs NT$0.048 profit in 3Q 2024) Third quarter 2025 results: NT$0.01 loss per share (down from NT$0.048 profit in 3Q 2024). Revenue: NT$115.5m (down 8.6% from 3Q 2024). Net loss: NT$1.47m (down 126% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (NT$2.60b market cap, or US$84.0m). Reported Earnings • Aug 13
Second quarter 2025 earnings released: EPS: NT$0.07 (vs NT$0.071 in 2Q 2024) Second quarter 2025 results: EPS: NT$0.07 (down from NT$0.071 in 2Q 2024). Revenue: NT$126.2m (flat on 2Q 2024). Net income: NT$7.34m (down 8.1% from 2Q 2024). Profit margin: 5.8% (down from 6.3% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Declared Dividend • Aug 07
Dividend reduced to NT$0.10 Dividend of NT$0.10 is 33% lower than last year. Ex-date: 20th August 2025 Payment date: 24th September 2025 Dividend yield will be 0.5%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 60%. Cash payout ratio: 20%. Reported Earnings • May 14
First quarter 2025 earnings released: EPS: NT$0.09 (vs NT$0.15 in 1Q 2024) First quarter 2025 results: EPS: NT$0.09 (down from NT$0.15 in 1Q 2024). Revenue: NT$131.3m (down 5.8% from 1Q 2024). Net income: NT$9.55m (down 43% from 1Q 2024). Profit margin: 7.3% (down from 12% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Annonce • Apr 30
Genovate Biotechnology Co., Ltd. to Report Q1, 2025 Results on May 08, 2025 Genovate Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on May 08, 2025 Reported Earnings • Mar 22
Full year 2024 earnings released: EPS: NT$0.23 (vs NT$0.26 in FY 2023) Full year 2024 results: EPS: NT$0.23 (down from NT$0.26 in FY 2023). Revenue: NT$510.9m (down 3.3% from FY 2023). Net income: NT$25.7m (down 12% from FY 2023). Profit margin: 5.0% (down from 5.6% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Mar 14
Genovate Biotechnology Co., Ltd., Annual General Meeting, May 29, 2025 Genovate Biotechnology Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: no,1, kung yeh 1st rd., hukou township, hsinchu county Taiwan Annonce • Mar 04
Genovate Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Mar 11, 2025 Genovate Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Mar 11, 2025 Buy Or Sell Opportunity • Jan 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.9% to NT$20.90. The fair value is estimated to be NT$26.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Dec 19
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.5% to NT$20.90. The fair value is estimated to be NT$26.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Dec 11
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.1% Last year net profit margin: 5.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (3.1% net profit margin). Market cap is less than US$100m (NT$2.43b market cap, or US$74.7m). Annonce • Oct 27
Genovate Biotechnology Co., Ltd. to Report Q3, 2024 Results on Nov 05, 2024 Genovate Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Nov 05, 2024 Upcoming Dividend • Aug 14
Upcoming dividend of NT$0.15 per share Eligible shareholders must have bought the stock before 21 August 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Taiwanese dividend payers (4.4%). Lower than average of industry peers (2.2%). Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.12 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.07 (down from NT$0.12 in 2Q 2023). Revenue: NT$126.9m (down 9.6% from 2Q 2023). Net income: NT$7.99m (down 41% from 2Q 2023). Profit margin: 6.3% (down from 9.7% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annonce • Jul 27
Genovate Biotechnology Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024 Genovate Biotechnology Co., Ltd. announced that they will report Q2, 2024 results on Aug 06, 2024 Annonce • Jun 01
Genovate Biotechnology Co., Ltd. Appoints Su, Lau-Shou as Independent Director Genovate Biotechnology Co., Ltd. announced the appointment of Su, Lau-Shou as independent director. Effective date of the new appointment is May 31, 2024. Annonce • May 29
Genovate Announces Plans to Submit New Drug Application for PMR to the U.S. Food & Drug Administration in the Second Half of 2025 Genovate Biotechnology Co., Ltd. announced its plans to submit a New Drug Application (NDA) with the United States Food and Drug Administration (US FDA) for PMR, an investigational once daily extended-release form of cilostazol for the treatment of Intermittent Claudication, in the second half of 2025. In the written responses to the pre-NDA meeting package, the FDA confirmed that the clinical studies conducted are sufficient to support the submission of a marketing application under the 505(b)(2) regulatory pathway. The key study in the submission package, GBL23-001 (NCT06167265), is a randomized, fully replicate crossover study designed to evaluate the bioequivalence and within-subject variability between PMR 145 mg once daily and the immediate-release tablet of cilostazol 100 mg twice daily. This study is expected to be completed in mid-2024, and the top-line results have shown that the primary endpoints of the study were achieved, and the decision to submit the application was made following the successful outcome of study GBL23-001. Furthermore, Genovate has been improving the PMR formulation and its manufacturing processes in order to address additional FDA comments. All clinical study and manufacturing data are expected to be included in the final submission package. PMR (Cilostazol Extended-Release Tablets) PMR, a novel extended-release (ER) formulation of cilostazol, was designed to reduce the concentration-dependent side effects associated with immediate-release (IR) tablet form of cilostazal. Cilostazol is currently available in IR tablet form at 50 and 100 mg strengths administered twice daily. The IR formulation of cilostazal, marketed as Pletal®? in the US (Pletaal®? in Taiwan and other Asian countries), was first available in Japan in 1988 for the treatment of peripheral arterial diseases and the prevention of recurrence of cerebral infarction and later approved by the US FDA in 1999 for the treatment of intermittent claudication (IC). Cilostazol is a specific PDE III inhibitor that can cause reduced platelet aggregation and increased vasodilatation. Cilostazol showed good efficacy in preventing secondary strokes, notably reducing the rates of ischaemic stroke recurrence. Nevertheless, the results from eight placebo-controlled clinical trials indicated that 15.4% of patients withdrawn from cilostazol treatment were as a result of adverse reactions. Headache, palpitations, and diarrhea were the most frequently reported adverse reactions among these patients. These adverse reactions were attributable to the peak concentration of cilostazol. Genovate is developing an ER tablet form of cilostrazol, PMR, to be administered once daily aiming to improve adherence and to reduce the side effects associated with the high peak-to-trough variation of the concentration of cilostazal IR. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.15 (vs NT$0.12 in 1Q 2023) First quarter 2024 results: EPS: NT$0.15 (up from NT$0.12 in 1Q 2023). Revenue: NT$139.4m (up 5.9% from 1Q 2023). Net income: NT$16.6m (up 27% from 1Q 2023). Profit margin: 12% (up from 9.9% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Apr 28
Genovate Biotechnology Co., Ltd. to Report Q1, 2024 Results on May 07, 2024 Genovate Biotechnology Co., Ltd. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 07, 2024 Reported Earnings • Apr 02
Full year 2023 earnings released: EPS: NT$0.27 (vs NT$0.11 loss in FY 2022) Full year 2023 results: EPS: NT$0.27 (up from NT$0.11 loss in FY 2022). Revenue: NT$528.5m (up 21% from FY 2022). Net income: NT$29.3m (up NT$41.7m from FY 2022). Profit margin: 5.6% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annonce • Mar 14
Genovate Biotechnology Co., Ltd., Annual General Meeting, May 31, 2024 Genovate Biotechnology Co., Ltd., Annual General Meeting, May 31, 2024. Location: No. 1, First Industrial Road, Huko Township Hsinchu County Taiwan Agenda: To consider 2023 business report; to consider audit Committee's review of the 2023 annual final accounting ledgers and statements; to consider report on 2023 employees' and directors' remuneration; to consider report on Cash Dividend of 2023 Annual Profit Distribution; to consider acknowledgment of the 2023 annual final accounting ledgers and statements; to consider acknowledgment of the 2023 Profit Distribution; to consider election of one additional Independent director;and to consider other issues. Reported Earnings • Nov 11
Third quarter 2023 earnings released: EPS: NT$0.16 (vs NT$0.065 in 3Q 2022) Third quarter 2023 results: EPS: NT$0.16 (up from NT$0.065 in 3Q 2022). Revenue: NT$137.1m (up 19% from 3Q 2022). Net income: NT$17.0m (up 142% from 3Q 2022). Profit margin: 12% (up from 6.1% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.03 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.12 (up from NT$0.03 in 2Q 2022). Revenue: NT$140.4m (up 30% from 2Q 2022). Net income: NT$13.6m (up 325% from 2Q 2022). Profit margin: 9.7% (up from 3.0% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. New Risk • Jul 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.07b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.07b market cap, or US$99.1m). Upcoming Dividend • Jun 29
Upcoming dividend of NT$0.17 per share at 0.6% yield Eligible shareholders must have bought the stock before 06 July 2023. Payment date: 04 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 0.6%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.6%). Annonce • May 30
Genovate Biotechnology Co., Ltd. Approves Election of Directors Genovate Biotechnology Co., Ltd. announced that at its AGM held on May 29, 2023, the shareholders approved election of directors. Director: National Development Fund, Representative: Huang,Chi-Ying; Director: National Development Fund, Representative: Chen,Hsiu-hui; Director: Chen, Jen; Director: Chu,Chia-Chen; Independent director: Lee,Shih-Jen; Independent director: Liu,Ke-Yi; Independent director: Chang,Chin-Ming. Reported Earnings • Mar 28
Full year 2022 earnings released: NT$0.11 loss per share (vs NT$0.003 profit in FY 2021) Full year 2022 results: NT$0.11 loss per share (down from NT$0.003 profit in FY 2021). Revenue: NT$438.8m (up 1.0% from FY 2021). Net loss: NT$12.3m (down NT$12.7m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. No independent directors (9 non-independent directors). Director Hui Po Wang was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: NT$0.07 (vs NT$0.07 loss in 3Q 2021) Third quarter 2022 results: EPS: NT$0.07 (up from NT$0.07 loss in 3Q 2021). Revenue: NT$115.3m (down 2.4% from 3Q 2021). Net income: NT$7.02m (up NT$14.5m from 3Q 2021). Profit margin: 6.1% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.027 loss in 2Q 2021) Second quarter 2022 results: EPS: NT$0.03 (up from NT$0.027 loss in 2Q 2021). Revenue: NT$108.5m (up 8.2% from 2Q 2021). Net income: NT$3.20m (up NT$6.11m from 2Q 2021). Profit margin: 3.0% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Jul 13
Upcoming dividend of NT$0.35 per share Eligible shareholders must have bought the stock before 20 July 2022. Payment date: 18 August 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Taiwanese dividend payers (6.9%). Lower than average of industry peers (2.9%). Reported Earnings • May 16
First quarter 2022 earnings released: NT$0.09 loss per share (vs NT$0.08 profit in 1Q 2021) First quarter 2022 results: NT$0.09 loss per share (down from NT$0.08 profit in 1Q 2021). Revenue: NT$99.7m (down 3.8% from 1Q 2021). Net loss: NT$9.39m (down 209% from profit in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. No independent directors (9 non-independent directors). Director Hui Po Wang was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: NT$0.003 (vs NT$0.36 in FY 2020) Full year 2021 results: EPS: NT$0.003 (down from NT$0.36 in FY 2020). Revenue: NT$434.3m (down 8.1% from FY 2020). Net income: NT$372.0k (down 99% from FY 2020). Profit margin: 0.1% (down from 8.2% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 15
Third quarter 2021 earnings released: NT$0.07 loss per share (vs NT$0.13 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$118.2m (down 2.7% from 3Q 2020). Net loss: NT$7.53m (down 153% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 03
Upcoming dividend of NT$0.41 per share Eligible shareholders must have bought the stock before 10 September 2021. Payment date: 15 October 2021. Trailing yield: 1.7%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.3%). Reported Earnings • Aug 18
Second quarter 2021 earnings released: NT$0.03 loss per share (vs NT$0.13 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: NT$100.3m (down 19% from 2Q 2020). Net loss: NT$2.91m (down 121% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • May 16
First quarter 2021 earnings released: EPS NT$0.08 (vs NT$0.18 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$103.6m (down 24% from 1Q 2020). Net income: NT$8.65m (down 53% from 1Q 2020). Profit margin: 8.4% (down from 14% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 26
Full year 2020 earnings released: EPS NT$0.37 (vs NT$0.32 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$472.7m (up 1.5% from FY 2019). Net income: NT$38.7m (up 14% from FY 2019). Profit margin: 8.2% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Annonce • Mar 19
Genovate Biotechnology Co., Ltd., Annual General Meeting, May 31, 2021 Genovate Biotechnology Co., Ltd., Annual General Meeting, May 31, 2021. Is New 90 Day High Low • Jan 07
New 90-day low: NT$29.00 The company is down 9.0% from its price of NT$31.70 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: NT$29.05 The company is down 17% from its price of NT$35.15 on 11 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 13% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: EPS NT$0.14 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$121.4m (up 10% from 3Q 2019). Net income: NT$14.3m (up 267% from 3Q 2019). Profit margin: 12% (up from 3.5% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 29
New 90-day low: NT$29.50 The company is down 25% from its price of NT$39.26 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Oct 12
New 90-day low: NT$30.90 The company is down 35% from its price of NT$47.21 on 14 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: NT$31.50 The company is down 6.0% from its price of NT$33.43 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. 
